共 50 条
Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings
被引:25
|作者:
Mehta, Ushma
[2
]
Clerk, Christine
[3
]
Allen, Elizabeth
[4
]
Yore, Mackensie
[5
]
Sevene, Esperanca
[6
]
Singlovic, Jan
[7
]
Petzold, Max
[8
]
Mangiaterra, Viviana
[1
]
Elefant, Elizabeth
[9
]
Sullivan, Frank M.
Holmes, Lewis B.
[10
]
Gomes, Melba
[1
]
机构:
[1] World Hlth Org, CH-27 Geneva, Switzerland
[2] Independent Pharmacovigilance Consultant, ZA-7708 Cape Town, Kenilworth, South Africa
[3] Univ Ghana, Sch Publ Hlth, Dept Epidemiol & Dis Control, Legon, Ghana
[4] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[5] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[6] Eduardo Mondlane Univ, Manhica Fdn, Dept Pharmacol, Maputo, Mozambique
[7] Data Management Consultant, Libochovany 41103, Czech Republic
[8] Univ Gothenburg, Sahlgrenska Acad, Dept Med, Ctr Applies Biostat, Gothenburg, Sweden
[9] Hop Armand Trousseau, Grp Hosp Univ Est, CRAT, F-75571 Paris 12, France
[10] Massachusetts Gen Hosp Children, Genet Unit, Boston, MA 02114 USA
来源:
BMC PREGNANCY AND CHILDBIRTH
|
2012年
/
12卷
关键词:
Pregnancy Registry;
Congenital anomaly;
Pharmacovigilance;
Teratogenicity;
Drug exposure;
Antiretrovirals;
Antimalarials;
Birth defects;
Neonates;
Safety;
Resource-limited settings;
NEURAL-TUBE DEFECTS;
CONGENITAL-MALFORMATIONS;
ANTIRETROVIRAL THERAPY;
NEWBORN-INFANTS;
WOMEN;
EFAVIRENZ;
DISTRICT;
SAFETY;
D O I:
10.1186/1471-2393-12-89
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
Background: The absence of robust evidence of safety of medicines in pregnancy, particularly those for major diseases provided by public health programmes in developing countries, has resulted in cautious recommendations on their use. We describe a protocol for a Pregnancy Registry adapted to resource-limited settings aimed at providing evidence on the safety of medicines in pregnancy. Methods/Design: Sentinel health facilities are chosen where women come for prenatal care and are likely to come for delivery. Staff capacity is improved to provide better care during the pregnancy, to identify visible birth defects at delivery and refer infants with major anomalies for surgical or clinical evaluation and treatment. Consenting women are enrolled at their first antenatal visit and careful medical, obstetric and drug-exposure histories taken; medical record linkage is encouraged. Enrolled women are followed up prospectively and their histories are updated at each subsequent visit. The enrolled woman is encouraged to deliver at the facility, where she and her baby can be assessed. Discussion: In addition to data pooling into a common WHO database, the WHO Pregnancy Registry has three important features: First is the inclusion of pregnant women coming for antenatal care, enabling comparison of birth outcomes of women who have been exposed to a medicine with those who have not. Second is its applicability to resource-poor settings regardless of drug or disease. Third is improvement of reproductive health care during pregnancies and at delivery. Facility delivery enables better health outcomes, timely evaluation and management of the newborn, and the collection of reliable clinical data. The Registry aims to improves maternal and neonatal care and also provide much needed information on the safety of medicines in pregnancy.
引用
收藏
页数:13
相关论文